CymaBay Therapeutics to Present at Upcoming Investor Conferences

Rhea-AI Summary

CymaBay Therapeutics, Inc. (NASDAQ: CBAY) announced its participation in two virtual investor conferences: the 11th Annual SVB Leerink Global Healthcare Conference from February 14-18, 2022, and Oppenheimer’s 32nd Annual Healthcare Conference on March 15-16, 2022. Management will present on February 17 at 3:00 PM ET and March 16 at 4:40 PM ET, respectively. CymaBay is focused on therapies for liver diseases, notably seladelpar for primary biliary cholangitis, which has received breakthrough and orphan drug designations from regulatory agencies.

NEWARK, Calif., Feb. 10, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management will participate in two virtual investor conferences including the 11^th Annual SVB Leerink Global Healthcare Conference taking place February 14-18, 2022 and Oppenheimer’s 32nd Annual Healthcare Conference taking place March 15-16, 2022.

11th Annual SVB Leerink Global Healthcare Conference
Date:	Thursday, February 17
Time:	3:00pm Eastern Time Fireside Chat
Webcast:	http://ir.cymabay.com/events
Oppenheimer’s 32nd Annual Healthcare Conference
Date:	Wednesday, March 16
Time:	4:40pm Eastern Time Fireside Chat
Webcast:	http://ir.cymabay.com/events

About CymaBay
CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on improving the lives of people with liver and other chronic diseases that have high unmet medical need through a pipeline of innovative therapies. Our deep understanding of the underlying mechanisms of liver inflammation and fibrosis, and the unique targets that play a role in their progression, have helped us receive breakthrough therapy designation (U.S. Food and Drug Administration), PRIority MEdicines status (European Medicines Agency) and orphan drug status (U.S. and Europe) for seladelpar, a first-in-class treatment for people with primary biliary cholangitis (PBC). Our evidence-based decision-making and commitment to the highest quality standards reflect our relentless dedication to the people, families and communities we serve. To learn more, visit www.cymabay.com and follow us on Twitter and Linkedin.

Cautionary Statements
Any statements made in this press release and at the investor conferences referenced above regarding the potential for seladelpar to treat PBC and potentially improve clinical symptoms of the disease, the potential benefits to patients, its current and future clinical trials, including the timing of enrollment in RESPONSE, the impact of the COVID pandemic on the enrollment timeline for CymaBay’s clinical trials, and CymaBay’s ability to fund current and planned clinical trials are forward looking statements that are subject to risks and uncertainties. Actual results and the timing of events regarding the further development of seladelpar could differ materially from those anticipated in such forward-looking statements as a result of risks and uncertainties, which include, without limitation, risks related to: the success, cost and timing of any of CymaBay's product development activities, including clinical trials; effects observed in trials to date that may not be repeated in the future; any delays or inability to obtain or maintain regulatory approval of CymaBay's product candidates in the United States or worldwide; the potential emergence of other COVID variants; and the ability of CymaBay to obtain sufficient financing to complete development, regulatory approval and commercialization of its product candidates in the United States and worldwide. Additional risks relating to CymaBay are contained in CymaBay's filings with the Securities and Exchange Commission, including without limitation its most recent Annual Report on Form 10-K and other documents subsequently filed with or furnished to the Securities and Exchange Commission. CymaBay disclaims any obligation to update these forward-looking statements except as required by law.

For additional information about CymaBay visit www.cymabay.com.

Public Relations Contact:

Glenn Silver
Lazar-FINN Partners
(973) 818-8198
Glenn.silver@finnpartners.com

Investor Relations Contact:

Hans Vitzthum
LifeSci Advisors, LLC
(617) 430-7578
Hans@LifeSciAdvisors.com

FAQ

What investor conferences is CymaBay participating in February and March 2022?

CymaBay is participating in the 11th Annual SVB Leerink Global Healthcare Conference from February 14-18, 2022, and Oppenheimer’s 32nd Annual Healthcare Conference on March 15-16, 2022.

When will CymaBay present at the SVB Leerink Global Healthcare Conference?

CymaBay will present on February 17, 2022, at 3:00 PM ET during the SVB Leerink Global Healthcare Conference.

What is the focus of CymaBay Therapeutics?

CymaBay Therapeutics focuses on developing therapies for liver diseases and other chronic conditions with high unmet medical needs.

What is seladelpar and its significance for CymaBay?

Seladelpar is a first-in-class treatment for primary biliary cholangitis and has received breakthrough designation and orphan drug status from regulatory agencies.

What are the dates and times for CymaBay's presentation at Oppenheimer’s Healthcare Conference?

CymaBay will present on March 16, 2022, at 4:40 PM ET during Oppenheimer’s 32nd Annual Healthcare Conference.